Figure 1. Suppression of IL-6–induced p-STAT3 persists in tocilizumab-treated but not siltuximab-treated patient PBMCs.

Each line represents an individual patient; n = 10 for siltuximab and n = 9 for tocilizumab. (A) Frequency of mbIL-6R⁺ cells in naive CD4⁺ T cell compartment at baseline. (B) Frequency of IL-6–induced p-STAT3⁺ cells in the naive CD4⁺ T cell compartment. Thawed and rested PBMCs from siltuximab-treated or tocilizumab-treated patients with T1D were stimulated with recombinant IL-6 (2 ng/mL) for 10 minutes.